Safe Muscle Relaxants in Children
For pediatric anesthesia, rocuronium and cisatracurium are the safest non-depolarizing muscle relaxants, while suxamethonium remains safe for rapid sequence intubation when used at age-appropriate doses with atropine co-administration in children under 3 years. 1
Age-Appropriate Dosing for Suxamethonium
When rapid onset is required, suxamethonium can be safely used with the following age-specific doses 1:
- < 1 month: 1.8 mg/kg
- 1 month to 1 year: 2.0 mg/kg
- 1-10 years: 1.2 mg/kg
- > 10 years: 1.0 mg/kg
Critical safety requirement: Always co-administer atropine (0.02 mg/kg) in children under 3 years to prevent bradycardia or cardiac arrest 1.
Non-Depolarizing Muscle Relaxants
Rocuronium
- Standard intubating dose: 0.6 mg/kg provides excellent intubation conditions with hemodynamic stability 2
- Higher doses (>0.9 mg/kg): May serve as alternative to suxamethonium for rapid sequence intubation 1
- Onset time varies by age: In infants 2-12 months, higher doses accelerate onset by approximately 30 seconds 3
Cisatracurium
- Dose: 0.05 mg/kg is safe and effective across pediatric age groups 2
- Advantage: Predictable recovery profile without significant hemodynamic effects
- Special consideration: Infants under 1 year are more sensitive and require 50-75% dose reduction in certain conditions 1
Mivacurium
- Ages 2-12 months: 0.15-0.2 mg/kg
- Ages >1 year: 0.2-0.25 mg/kg
- Key safety finding: No significant histamine release at studied doses across all pediatric age groups 3
Critical Contraindications
Absolute contraindications for suxamethonium 1:
- Primary muscle damage (myopathies, muscular dystrophy)
- Myotonia (risk of generalized contraction with rhabdomyolysis)
- Chronic motor deficits with nAChR up-regulation
- Extensive/deep burns (after initial days)
- Prolonged critical illness
These conditions can cause life-threatening hyperkalaemia or rhabdomyolysis with suxamethonium administration.
Neuromuscular Disease Considerations
In patients with neuromuscular disorders, non-depolarizing relaxants require significant dose adjustments 1:
- Myasthenia gravis: 50-75% dose reduction needed (increased sensitivity)
- Duchenne muscular dystrophy: Markedly prolonged onset and recovery with rocuronium 0.6 mg/kg
- Chronic denervation: Increased resistance requiring higher doses
Mandatory monitoring: Neuromuscular blockade monitoring is strongly recommended in all children with neuromuscular disease to avoid overdosing 1.
Essential Monitoring
Residual neuromuscular blockade occurs in 28% of pediatric patients receiving muscle relaxants 1. Intraoperative neuromuscular monitoring is recommended for all pediatric cases to prevent residual paralysis and associated complications.
Common Pitfalls to Avoid
Failing to adjust for age-related pharmacodynamics: Infants <1 year are more sensitive to non-depolarizing agents on a weight basis but appear resistant when dosed by surface area 4
Omitting atropine with suxamethonium: This is a critical safety measure in young children to prevent life-threatening bradycardia 1
Using suxamethonium in undiagnosed myopathy: Always screen for muscle disease history before administration
Inadequate reversal planning: Ensure immediate availability of reversal agents, particularly in patients with neuromuscular disease 1